The aim of this protocol is to perform a first randomized controlled trial evaluating how
Tezepelumab affects the bronchial morphology (and computed tomographic variables in general)
of asthmatic patients. In parallel, the investigators also hope to reproduce clinical
benefits and perform a transcriptomic study that will juxtapose changes in genetic expression
with changes in bronchial morphology and inflammatory signatures. The general hypothesis is
that tezepelumab treatment is capable of at least partially reversing bronchial remodelling
as detected on computed-tomographic (CT) scans. The investigators also expect such reversal
to occur within a unique physiological repair environment that will be reflected by
transcriptomic profiles